Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › SURPASS-CVOT

SURPASS-CVOT

Tirzepatide · T2D + established ASCVD

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Tirzepatide
Population
T2D + established ASCVD
Official title
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed · 2020-05 → 2025-06
Participants
13299
Registry
NCT04255433

Cardiovascular and kidney outcomes

SURPASS-CVOT tirzepatide 5–15 mg vs dulaglutide 1.5 mg (active) · T2D + established ASCVD · n = 13299 · 2025 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE (vs dulaglutide) primary
Composite of death from cardiovascular causes, myocardial infarction, or stroke (95.3% CI reported, adjusted for interim analysis)
0.920.83–1.01801 vs 862verified
Cardiovascular death
Death from cardiovascular causes
0.890.77–1.02367 vs 408verified
All-cause death
Death from any cause
0.840.75–0.94566 vs 669verified
Myocardial infarction
Myocardial infarction (the text does not specify fatal or non-fatal; component of primary composite)
0.860.74–1.00311 vs 357verified
Stroke
Stroke (the text does not specify fatal or non-fatal; component of primary composite)
0.910.76–1.09229 vs 249verified
CV death or worsening HF
Composite of death from cardiovascular causes or hospitalization or urgent visit for heart failure
0.910.81–1.03512 vs 557verified
Expanded MACE (MACE + revasc.)
4-point composite: death from CV causes, myocardial infarction, stroke, or coronary revascularization (secondary end point); comparator dulaglutide 1.5 mg (active control)
0.880.81–0.961089 vs 1217verified
Verbatim quotes (7)
  • 3-point MACE (vs dulaglutide) · Abstract; Results, paragraph 1; Table 2
    A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01
  • Cardiovascular death · Results, paragraph 1; Table 2
    Death from cardiovascular causes occurred in 367 patients (5.6%) in the tirzepatide group and 408 (6.2%) in the dulaglutide group (hazard ratio, 0.89; 95% CI, 0.77 to 1.02).
  • All-cause death · Results, paragraph 1; Table 2
    Death from any cause occurred in 566 patients (8.6%) in the tirzepatide group and 669 (10.2%) in the dulaglutide group (hazard ratio, 0.84; 95% CI, 0.75 to 0.94)
  • Myocardial infarction · Results, paragraph 1; Table 2
    Myocardial infarction occurred in 311 patients (4.7%) and 357 patients (5.4%), respectively (hazard ratio, 0.86; 95% CI, 0.74 to 1.00).
  • Stroke · Results, paragraph 1; Table 2
    Stroke occurred in 229 patients (3.5%) and 249 patients (3.8%), respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.09).
  • CV death or worsening HF · Results, paragraph 1; Table 2
    Death from cardiovascular causes or hospitalization or urgent visit for heart failure ... occurred in 512 patients (7.8%) in the tirzepatide group and 557 (8.5%) ... (hazard ratio, 0.91; 95% CI, 0.81 to 1.03)
  • Expanded MACE (MACE + revasc.) · Table 2, key secondary end points
    | Death from cardiovascular causes, myocardial infarction, stroke, or coronary revascularization — no. (%) | 1089 (16.5) | 1217 (18.5) | 0.88 (0.81 to 0.96) |

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: SURPASS-CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surpass-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.